对 8例肺癌患者 (伴轻度肾功能损害 )和 8例肺感染病人单剂量静滴环丙沙星 (ciprofloxacin,CPL X) 4 0 0 mg的药代动力学进行了研究。采用微生物法测定 CPL X的血清浓度 ,以 3P97药代动力学程序拟合计算。结果表明 :与肺感染组相比 ,肺癌组的 Vc、AU C、T1 / 2α、T1 / 2β及 CLS等主要药代动力学参数均无显著改变 ,提示 CPL X在肺癌患者 (伴轻度肾功能损害 )体内的药代动力学未发生明显改变。结论 :肺癌患者 (伴轻度肾功能损害 )应用 CPL X时 ,无需调整给药方案。 Pharmacokinetics of a single dose of 400 mg of ciprofloxacin (CPL X) in 8 patients with lung cancer (with mild renal impairment) and 8 patients with pulmonary infection was studied. The serum concentration of CPL X was determined by the microbiological method and was calculated by fitting the 3P97 pharmacokinetic program. The results showed that the main pharmacokinetic parameters of Vc, AU C, T1 / 2α, T1 / 2β and CLS in lung cancer group had no significant change compared with those in lung infection group, which indicated that CPL X had no significant change in patients with lung cancer Functional impairment) in vivo pharmacokinetics did not change significantly. Conclusions: There is no need to adjust dosing regimens for patients with lung cancer (with mild renal impairment) using CPL X.